San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

MonarchE is an ongoing, open-label phase 3 study designed to evaluate invasive disease-free survival in patients with hormone receptor‒positive, HER2-negative advanced breast cancer receiving abemaciclib plus standard-of-care adjuvant endocrine therapy (ET). Read More ›

Abemaciclib demonstrated efficacy and an acceptable safety profile in treating brain metastases in hormone receptor (HR)-positive/HER2-negative breast cancer, but was not effective for brain metastases in HR-positive/HER2-positive breast cancer. Read More ›

The combination of the selective histone deacetylase inhibitor entinostat plus a CDK4/6 inhibitor demonstrates greater synergistic antitumor activity against estrogen receptor (ER)-positive breast cancer and triple-negative (TN) breast cancer than either agent alone. Read More ›

The addition of Ra-223 to hormonal therapy and denosumab is a feasible and safe combination therapy in patients with hormone receptor (HR)-positive breast cancer with bone-dominant metastasis. Read More ›

In a subanalysis of the MONARCH 2 and 3 studies, patients with hormone receptor–positive, HER2-negative breast cancer with poor prognostic factors received greater benefit from the addition of abemaciclib to endocrine therapy than those without a poor prognosis. Read More ›

In the MONALEESA-2 study, the CDK4/6 inhibitor ribociclib, in combination with letrozole, led to significant prolongation of progression-free survival while maintaining quality of life in postmenopausal women with advanced breast cancer. Read More ›

The combination of abemaciclib plus endocrine therapy is an effective treatment option in patients with hormone receptor–positive, HER2-negative advanced breast cancer with liver metastases, with significantly higher clinical benefits than those derived from single-agent endocrine therapy. Read More ›

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›

Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›

Page 10 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications